|
May 9
|
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
|
|
May 8
|
Just Say No to Drugs: 3 Pharma Stocks to Avoid
|
|
May 3
|
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
|
|
May 3
|
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar
|
|
May 3
|
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
May 2
|
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
|
|
May 2
|
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
|
|
Apr 29
|
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
|
|
Apr 25
|
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 25
|
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
|
|
Apr 14
|
2 Stocks Down 30% to Buy Right Now
|
|
Apr 12
|
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
|
|
Apr 9
|
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
|
|
Apr 6
|
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65%
|
|
Mar 28
|
Better Cathie Wood Stock: Moderna vs. Intellia
|
|
Mar 21
|
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
|
|
Mar 21
|
3 Stocks That Could Be the Next Big Thing in Gene Editing
|
|
Mar 19
|
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
|
|
Mar 18
|
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
|
|
Mar 9
|
Is Intellia Therapeutics Stock a Buy Now?
|